Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI may help decide who gets immunotherapy after liver cancer surgery

NCT ID NCT07379489

Not yet recruiting Disease control Sponsor: Tongji Hospital Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study will test whether a deep learning computer model can help doctors decide which liver cancer patients should receive immunotherapy (PD-1 inhibitors) after surgery to prevent the cancer from returning. About 300 patients who have had their liver cancer completely removed will be followed to see if the model's recommendations improve how long they stay cancer-free. The goal is to personalize treatment based on the type of recurrence risk.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
PD-1 inhibitors (a type of immunotherapy that helps the immune system attack cancer cells)
What this could lead to
If successful, this could provide a personalized way to use immunotherapy after liver cancer surgery, potentially reducing the chance of cancer coming back.
What could go wrong
This trial hasn't started yet and is relatively small (300 people). The deep learning model may not accurately predict who benefits, and PD-1 inhibitors can cause immune-related side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADJUVANT THERAPY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADJUVANT THERAPY HCC IMMUNE CHECKPOINT INHIBITOR RECURRENCE

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.